Literature DB >> 18209092

Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.

Lena Schiffer1, Ramalingam Bethunaickan, Meera Ramanujam, Weiqing Huang, Mario Schiffer, Haiou Tao, Michael P Madaio, Michael M Madaio, Erwin P Bottinger, Anne Davidson.   

Abstract

Costimulatory blockade with CTLA4Ig and anti-CD40L along with a single dose of cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F(1) mice. To understand the mechanisms for remission and for impending relapse, we examined the expression profiles of 61 inflammatory molecules in the perfused kidneys of treated mice and untreated mice at different stages of disease. Further studies using flow cytometry and immunohistochemistry allowed us to determine the cellular origins of several key markers. We show that only a limited set of inflammatory mediators is expressed in the kidney following glomerular immune complex deposition but before the onset of proteinuria. Formation of a lymphoid aggregate in the renal pelvis precedes the invasion of the kidney by inflammatory cells. Regulatory molecules are expressed early in the disease process and during remission but do not prevent the inevitable progression of active inflammation. Onset of proliferative glomerulonephritis and proteinuria is associated with activation of the renal endothelium, expression of chemokines that mediate glomerular cell infiltration, and infiltration by activated dendritic cells and macrophages that migrate to different topographical areas of the kidney but express a similar profile of inflammatory cytokines. Increasing interstitial infiltration by macrophages and progressive tubular damage, manifested by production of lipocalin-2, occur later in the disease process. Studies of treated mice identify a type II (M2b)-activated macrophage as a marker of remission induction and impending relapse and suggest that therapy for systemic lupus erythematosus nephritis should include strategies that prevent both activation of monocytes and their migration to the kidney.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209092      PMCID: PMC2587994          DOI: 10.4049/jimmunol.180.3.1938

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Lupus nephritis: a clinical and pathologic study based on renal biopsies.

Authors:  R C MUEHRCKE; R M KARK; C L PIRANI; V E POLLAK
Journal:  Medicine (Baltimore)       Date:  1957-02       Impact factor: 1.889

2.  CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis.

Authors:  Ludmila V Bagaeva; Praveen Rao; James M Powers; Benjamin M Segal
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 3.  PD-1 and its ligands in T-cell immunity.

Authors:  Mary E Keir; Loise M Francisco; Arlene H Sharpe
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

4.  A role for BLyS in the activation of innate immune cells.

Authors:  Sook Kyung Chang; Bonnie K Arendt; Jaime R Darce; Xiaosheng Wu; Diane F Jelinek
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

Review 5.  Kidney diseases and chemokines.

Authors:  Ulf Panzer; Oliver M Steinmetz; Rolf A K Stahl; Gunter Wolf
Journal:  Curr Drug Targets       Date:  2006-01       Impact factor: 3.465

6.  Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

Authors:  L Llorente; Y Richaud-Patin; C García-Padilla; E Claret; J Jakez-Ocampo; M H Cardiel; J Alcocer-Varela; L Grangeot-Keros; D Alarcón-Segovia; J Wijdenes; P Galanaud; D Emilie
Journal:  Arthritis Rheum       Date:  2000-08

7.  Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice.

Authors:  G H Tesch; S Maifert; A Schwarting; B J Rollins; V R Kelley
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

8.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

9.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis.

Authors:  Jong-Dae Ji; Ioannis Tassiulas; Kyung-Hyun Park-Min; Ani Aydin; Ingrid Mecklenbrauker; Alexander Tarakhovsky; Luminita Pricop; Jane E Salmon; Lionel B Ivashkiv
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  100 in total

1.  Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Heiko Billing; Burkhard Tönshoff; Dieter Haffner; Jörg Dötsch; Gottfried Wechselberger; Lutz T Weber; Elisabeth Steichen-Gersdorf
Journal:  Pediatr Nephrol       Date:  2011-12-07       Impact factor: 3.714

2.  Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Authors:  Celine C Berthier; Ramalingam Bethunaickan; Tania Gonzalez-Rivera; Viji Nair; Meera Ramanujam; Weijia Zhang; Erwin P Bottinger; Stephan Segerer; Maja Lindenmeyer; Clemens D Cohen; Anne Davidson; Matthias Kretzler
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

3.  Distinct roles of CSF-1 isoforms in lupus nephritis.

Authors:  Julia Menke; Yasunori Iwata; Whitney A Rabacal; Ranu Basu; E Richard Stanley; Vicki R Kelley
Journal:  J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 10.121

Review 4.  Dendritic cells and macrophages in the kidney: a spectrum of good and evil.

Authors:  Natasha M Rogers; David A Ferenbach; Jeffrey S Isenberg; Angus W Thomson; Jeremy Hughes
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

5.  Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice.

Authors:  Ramalingam Bethunaickan; Celine C Berthier; Weijia Zhang; Ridvan Eksi; Hong-Dong Li; Yuanfang Guan; Matthias Kretzler; Anne Davidson
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

6.  [Relationship between podocyte injury and macrophage infiltration in renal tissues of patients with lupus nephritis].

Authors:  Y Wang; M H Li; Y Zhang; X Y Hu; R X Ma
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

Review 7.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

8.  Renal-infiltrating CD11c+ cells are pathogenic in murine lupus nephritis through promoting CD4+ T cell responses.

Authors:  X Liao; J Ren; A Reihl; T Pirapakaran; B Sreekumar; T E Cecere; C M Reilly; X M Luo
Journal:  Clin Exp Immunol       Date:  2017-08-18       Impact factor: 4.330

Review 9.  Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.

Authors:  Andras Perl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.

Authors:  Samantha A Chalmers; Jing Wen; Justine Shum; Jessica Doerner; Leal Herlitz; Chaim Putterman
Journal:  Clin Immunol       Date:  2016-08-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.